Bioaffinity Technologies, Inc. (BIAF) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Bioaffinity Technologies, Inc., a Delaware corporation, on May 12, 2026. The company is an emerging growth company with its principal executive offices in San Antonio, Texas. Its common stock and warrants trade on the Nasdaq Capital Market under the symbols BIAF and BIAFW, respectively.
Key Financial Metrics
The filing does not provide specific financial statements, revenue figures, profit margins, cash flow data, debt levels, or liquidity metrics. The report focuses exclusively on operational sales volume for a specific product line.
Material Changes
- Record Sales Volume: Unit sales for the CyPath® Lung diagnostic test achieved a record high in a single month.
- Year-Over-Year Growth: Preliminary unaudited data indicates unit sales for April 2026 increased nearly 300% compared to April 2025.
Guidance, Outlook, and Risks
The filing incorporates a press release (Exhibit 99.1) announcing the sales milestone but does not contain forward-looking guidance, management commentary on future financial performance, or specific risk factors within the text of this 8-K. The data cited is preliminary and unaudited.
Investor Verification Checklist
- Verify the full text of the press release attached as Exhibit 99.1 for additional context on the sales surge.
- Confirm the definition of "unit sales" and whether this metric correlates directly with revenue recognition.
- Review upcoming quarterly reports (10-Q) to see if the 300% increase in unit sales translates to material revenue growth.
- Assess the sustainability of the April 2026 sales spike versus historical trends.